The Total Effective Rate Is More Than 90%. Can Global Anti Epidemic Help Chinese Medicine Get Out Of The Sea?

The global pandemic of the new crown pneumonia has created an opportunity for Chinese medicine to go abroad.

As of April 10th, the total number of confirmed cases of new crown pneumonia in the world was 1582904, with 94807 deaths. So far, no new vaccines against the new crown virus have been found. But by combing China's epidemic experience, it will be found that Chinese medicine plays a very important role in the control of epidemic situation. Statistics show that 74187 of Chinese confirmed cases of new crown pneumonia use Chinese medicine, accounting for 91.5%. The clinical efficacy showed that the total effective rate of TCM was over 90%. This creates a historical opportunity for Chinese medicine to "go to sea".

On the evening of March 25th, Hu Jiqiang, chairman of the board of public health, said that Chinese medicine played an indispensable role in the prevention and control of the epidemic. The epidemic provided a good opportunity for Chinese medicine to go abroad and to the world.

It is understood that the number of Chinese medicine clinics in the United States, Italy, Holland, the United Kingdom, Hungary and other countries increased significantly. The number of Chinese herbal pieces and dispensing granules in clinics doubled. Among them, Lianhua Qingwen of Yiling pharmaceutical has been exported to Canada, Romania, Indonesia, Mozambique, Brazil, Hongkong, Macao, China and other countries. This helped Yiling pharmaceutical industry to grow significantly in the first quarter.

However, from the data point of view, the sales volume of anti epidemic Chinese medicine is not large. In fact, the export of Chinese herbal medicines and plant extracts has always been the main export of Chinese medicine, and the proportion of proprietary Chinese medicines is not high. In twenty-first Century, the economic report reporters obtained data from the Chinese medicine and health import and Export Chamber of Commerce, which showed that in 2019, Chinese medicine products were exported to US $4 billion 19 million, of which Chinese patent medicines exported US $263 million, down 0.45% from the same period last year.

? ? ? Shi Lichen, head of Beijing Ding Chen medical consultation management center, pointed out to the twenty-first Century economic report reporter that in the new crown pneumonia epidemic situation, the effect of Chinese medicine is obvious, and the relevant treatment plan is promoted worldwide, which has a certain boost for the whole Chinese medicine industry, but on the whole, as a drug, it needs to be accredited by the European and American countries. Certificates are eligible for market entry, and they need to be applied for clinical research. Otherwise, they can not be used as medicines for access to medical systems in these countries.

The central steering group expert, President of Tianjin University of Traditional Chinese Medicine and Zhang Boli, academician of the Chinese Academy of engineering, also said that Chinese medicine is going out, one is family needs, and the two is to rely on our excellent curative effect, relying on science and technology, and its foundation is its solid internal strength.

Global epidemic of Chinese Medicine

In this war, Chinese medicine is widely concerned for its effective relief of symptoms, reduction of mild illness to severe development, improvement of cure rate, and promotion of rehabilitation in the recovery stage. Recently, the WHO (WHO) revised the contents of traditional Chinese medicine through the eleventh revision of the international classification of diseases and related health issues, which is an international recognition of the role of Chinese medicine in improving human health and well-being.

It is understood that Jinhua Qingqing granule, Lianhua Qingwen capsule, Xuebijing injection and Qingfei detoxification decoction, Huashi Baidu Fang, Xuan lung toxin prescription "three drugs and three parties" represented a batch of Chinese medicine has been proved to have obvious curative effect, and they have become one of the choice directions of global epidemic medicine with the promotion of Chinese experience.

In March 23rd, Yu Yanhong, a spokesman for the China Administration of traditional Chinese medicine, said that the treatment plan used in China proved to be correct. China is willing to provide support for Chinese medicine and expert answers to other countries. At present, China has provided Chinese medicine to many countries in Italy.

On the afternoon of March 25th, medical experts from China, Germany, the United Kingdom, Italy and Romania carried out the China Europe anti epidemic meeting through online video. According to the 21 reporters online understanding, academician Zhong Nanshan briefed the experts on the experience of Chinese medicine and the related drugs.

A report from Zhong Nanshan to European experts showed that after using chloroquine, the proportion of suspected patients with a new crown virus RNA in a latent period of 10-14 days was very high. Zhong academician explained that in contrast treatment data, the proportion of RNA in chloroquine group was 91.4% and 95.9%, while that in control group was 57.4%. 284 patients treated with Lianhua Qingwen were 91.5%.

? ? ? Yiling pharmaceutical side also said that in view of the clinical effects of Lianhua Qingwen capsule and the rapid development of foreign epidemic situation in China, so far, Lianhua Qingwen capsule has obtained the registration approvals of 6 countries in Canada, Brazil, Romania, Thailand, Indonesia and Mozambique, and the listed license status includes "proprietary Chinese Medicine", "medicine", "plant", "plant", "medicine" and "plant". "Medicine", "natural health product", "food supplement", "modern plant medicine" and so on.

It is also known that anti epidemic Chinese patent medicines can guarantee timely supply. On April 8th, at the press conference of the State Council, Cao Xuejun, deputy director of the consumer goods industry department of the Ministry of industry and commerce, said that the resumption of production and production of key medical materials such as drugs had been traced and monitored, and the 14 Chinese patent medicines included in the new crown pneumonia diagnosis and treatment plan were monitored and monitored. Guaranteed. Up to now, Lianhua Qingwen capsules can reach 2 million boxes and stock 30 million boxes, and Jinhua Qingxin can reach 26 thousand boxes and 400 thousand boxes.

Thunder and heavy rain?

Although Chinese medicine is effective in the treatment of new crown pneumonia, it is not easy for overseas Chinese medicine to enter the hospital for epidemic prevention. Take the United States as an example, a Chinese girl living in Michigan introduced to the 21 reporters that the local pharmacies and medical institutions did not sell anti epidemic Chinese medicine. Many Chinese anti epidemic Chinese medicine products recommended by many Chinese diagnosis and treatment programs were mostly used in the Chinese circle, and they were mailed from the mainland.

An analyst who has been following the Chinese medicine for a long time says that at present, because of the great reputation of Chinese medicine in the world, in fact, in some western countries, the status of Chinese medicine has not been recognized in the western medicine law. At present, Chinese medicine decoction can not be used in hospitals.

It is understood that the current anti epidemic Chinese patent medicine sales in the global market is not large.

According to the data of China Medical and health import and export chamber, the proportion of proprietary Chinese medicines in China's traditional Chinese medicine exports is not high, accounting for only 6.53% of the total export volume of Chinese medicine products, which is still in a weak position relative to the raw material products.

Liu Yan, deputy director of the Chinese medicine and health import and Export Chamber of Commerce, pointed out that, under the influence of foreign policies and regulations, the external trade performance of Chinese patent medicines in 2019 was low, with an export volume of US $262 million, down 0.45% from the same period last year. Among them, the second largest export market of proprietary Chinese medicines in the United States decreased by 16.65% in 2019 compared with the same period last year. In addition, the average export price of Chinese patent drugs dropped by 11.28% last year.

A research and development director of a listed pharmaceutical company, cooperating with a Japanese Research Institute, told the 21 reporters that although China is the source of Chinese medicine, the largest share of Chinese herbal medicine in the global market is not China but Japan and South Korea.

For example, 75% of the raw materials for the production of Chinese traditional medicine in Japan are imported from China, and Japan's Tianjin village pharmaceutical company has more than 70 GAP bases at the source of Chinese herbal medicines. Tongrentang, as the most traditional GAP enterprise in China, has only 8 bases.

In the western mainstream medicine market, the registration of proprietary Chinese medicines as a drug in the United States has not yet achieved zero breakthroughs, and few can be successfully registered in the European Union.

According to the US FDA clinical trial website, only 10 Chinese herbal medicines have entered the clinical research stage through the application of FDA IND, of which only 3 kinds of Chinese medicine preparations have been allowed to enter the final stage III clinical trial.

The "star drug" Lianhua Qingwen capsule entered the FDA phase II of the United States at the end of 2015, and is now in the stage of collecting cases, and is still advancing according to the established plan. Yiling pharmaceutical related person in charge told the 21 reporters that the follow up was based on the announcement.

The sea dilemma should be solved from the source.

Shi Lichen told the 21 reporters that internationalization of Chinese medicine is a long-term process and faces greater challenges. Many western countries do not recognize that Chinese medicine is medicine. They believe that Chinese medicine lacks unified scientific standards, and Chinese patent medicines and Chinese herbal pieces are classified as dietary supplements or healthy foods. "The foreign recognized clinical data, the key to solve the sea dilemma is to solve the safety and effectiveness from the source."

According to the analysis of the above long-term tracer of Chinese medicine to the sea, due to the complexity of Chinese patent medicines, it is difficult to detect all the effective components with the instrument, which is difficult to meet the import requirements of Europe and the United States. Moreover, the use of Chinese medicines has many legal restrictions in Europe. For example, the EU has strict monitoring of heavy metals and pesticide residues, while some Chinese traditional medicine and chemical residues produced by China are higher than those of EU standards.

At the same time, Chinese medicine emphasizes one disease and one side, which makes it impossible for Chinese medicine to maintain norms quantitatively, but relies heavily on experienced TCM doctors and pharmacists. The resulting derivative problem is that there are many defects in the reliability of Chinese medicine on the one hand; on the other hand, practitioners who meet the qualification requirements have become a difficult problem for Chinese medicine to promote in overseas markets.

In fact, even in China, the approval of new Chinese medicine is not easy at present. Data showed that only 14 new Chinese medicines were approved in 2015~2019.

Zhang Boli believes that problems such as insufficient innovation and low level repetition are the main factors that impede the internationalization of Chinese medicine. It is necessary to establish a scientific and standardized Chinese medicine standard as soon as possible, and make Chinese herbal medicines a national strategic resource, and strengthen protection, research and development and reasonable utilization. At the same time, we should vigorously promote the standardized cultivation of Chinese medicinal materials to ensure the sustainable supply of Chinese herbal medicines. Ensure product quality and safety.

Liu Yan also pointed out that as the source of the quality of traditional Chinese medicine, the cultivation of Chinese herbal medicines has become the top priority. Many domestic high quality enterprises expect to enhance their overall capability through standardized management of the base, and provide the raw materials of Chinese medicine that meet the international market needs through standardized planting processes.

It is understood that the 2020 edition of Pharmacopoeia set higher requirements for the quality of Chinese herbal medicines. The new drug administration law has more severe penalties for counterfeit and shoddy medicinal materials. The curtain of industrial rectification will be opened, and the improvement of the quality of Chinese medicine will become the industry consensus.

Under the guidance of the policy of "one belt and one road", the recognition of the Chinese medicine and the recognition of the curative effect by the countries and regions along the line, especially the remarkable efficacy of the Chinese medicine produced by the epidemic, can promote the understanding of the world's Chinese medicine to some extent, and the export of Chinese patent medicines will be changed in the future. Liu Yan said.

?